{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:07:23Z","timestamp":1765609643509},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.lungcan.2015.05.021","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T18:20:57Z","timestamp":1433614857000},"page":"175-180","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership"],"prefix":"10.1016","volume":"89","author":[{"given":"R.J.","family":"Stephens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"Mesothelioma in Great Britain. Health and safety executive 2014. Available at: http:\/\/www.hse.gov.uk\/statistics\/causdis\/mesothelioma\/mesothelioma.pdf.","key":"10.1016\/j.lungcan.2015.05.021_bib0170"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0175","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1183\/09031936.00168111","article-title":"Mesothelioma incidence projections in South East England","volume":"40","author":"Riaz","year":"2012","journal-title":"Eur Respir J"},{"unstructured":"Kazan-Allen L. Asbestos: from Magic Mineral to Killer Dust. Available at: http:\/\/ibasecretariat.org\/lka-paper-asbestos-from-magic-mineral-to-killer-dust-apr-28-2013.pdf.","key":"10.1016\/j.lungcan.2015.05.021_bib0180"},{"unstructured":"National Lung Cancer Audit Report 2014: Mesothelioma. Report for the period 2008\u20132012. Available at: http:\/\/www.hscic.gov.uk\/catalogue\/PUB14876\/nati-lung-canc-audi-supp-prog-meso-2014-rep.pdf.","key":"10.1016\/j.lungcan.2015.05.021_bib0185"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0190","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2015.05.021_bib0195","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S0169-5002(14)70216-8","article-title":"PIT: a phase III trial of Prophylactic Irradiation of Tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention","volume":"83","author":"Bayman","year":"2014","journal-title":"Lung Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2015.05.021_bib0200","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0169-5002(14)70219-3","article-title":"Surgical and large bore pleural interventions in malignant pleural mesothelioma and radiotherapy trial (the SMART trial)","volume":"83","author":"Clive","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0205","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0210","first-page":"232","article-title":"The role of key genes and pathways involved in the tumorigenesis of malignant mesothelioma","volume":"1845","author":"de Assis","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0215","first-page":"449","article-title":"Biomarkers and prognostic factors for mesothelioma","volume":"1","author":"Pass","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.02.034","article-title":"Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies","volume":"322","author":"Izzi","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0225","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0230","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.hoc.2005.09.003","article-title":"Mesothelioma from the Patient's Perspective","volume":"19","author":"Clayson","year":"2005","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0235","series-title":"Malignant pleural mesothelioma","first-page":"402","article-title":"Palliative care in mesothelioma","author":"Ahmedzai","year":"2006"},{"year":"2013","first-page":"747","series-title":"Official report","key":"10.1016\/j.lungcan.2015.05.021_bib0240"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0245","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(04)17494-1","article-title":"The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials","volume":"364","author":"Partridge","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0250","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(10)60712-X","article-title":"The James Lind Alliance: tackling research mismatches","volume":"376","author":"Petit-Zeman","year":"2010","journal-title":"Lancet"},{"year":"2012","author":"Cowan","series-title":"The James Lind Alliance Guidebook. Oxford, UK","key":"10.1016\/j.lungcan.2015.05.021_bib0255"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0260","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1464-410X.2011.10609.x","article-title":"The James Lind Alliance approach to priority setting for prostate cancer research: an integrative methodology based on patient and clinician participation","volume":"108","author":"Lophatananon","year":"2011","journal-title":"Br J Urol Int"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0265","first-page":"530","article-title":"Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership","volume":"164","author":"Eleftheriadou","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0270","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/bmjspcare-2014-000838.3","article-title":"Research priority setting in palliative and end of life care: the James Lind Alliance approach consulting patients, carers and clinicians","volume":"5","author":"Best","year":"2015","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0275","doi-asserted-by":"crossref","first-page":"e006233","DOI":"10.1136\/bmjopen-2014-006233","article-title":"Setting research priorities to improve the health of children and young people with neurodisability: a British Academy of Childhood Disability-James Lind Alliance Research Priority Setting Partnership","volume":"5","author":"Morris","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0280","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-8-61","article-title":"Prioritization of therapy uncertainties in dystrophic epidermolysis bullosa: where should research direct to? An example of priority setting partnership in very rare disorders","volume":"8","author":"Davila-Seijo","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0285","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JAC.0b013e3181e62cda","article-title":"The James Lind Alliance \u2013 tackling treatment uncertainties together","volume":"33","author":"Cowan","year":"2010","journal-title":"J Ambul Care Manag"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0290","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bjd.12040","article-title":"The eczema priority setting partnership: a collaboration between patients, carers, clinicians, and researchers to identify and prioritise important research questions for the treatment of eczema","volume":"168","author":"Batchelor","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0295","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4155\/cli.12.129","article-title":"Identifying and prioritizing unmet research questions for people with tinnitus: the James Lind Alliance Tinnitus Priority Setting Partnership","volume":"3","author":"Hall","year":"2013","journal-title":"Clin Invest"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0300","doi-asserted-by":"crossref","first-page":"e004905","DOI":"10.1136\/bmjopen-2014-004905","article-title":"The Sight Loss and Vision Priority Setting partnership (SLV-PSP): overview and results of the research prioritization survey process","volume":"4","author":"Rowe","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0305","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1747-4949.2012.00942.x","article-title":"Top 10 research priorities relating to life after stroke \u2013 consensus from stroke survivors, caregivers, and health professionals","volume":"9","author":"Pollock","year":"2014","journal-title":"Int J Stroke"},{"unstructured":"UK Database of Uncertainties about the Effects of Treatments (DUETS). Available at: http:\/\/www.library.nhs.uk\/duets\/","key":"10.1016\/j.lungcan.2015.05.021_bib0310"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0315","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The wellbuilt clinical question: a key to evidence-based decisions","volume":"123","author":"Richardson","year":"1995","journal-title":"ACP J Club"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0320","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0325","first-page":"CD005574","article-title":"Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma","author":"Green","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lungcan.2015.05.021_bib0330","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"374","author":"Chalmers","year":"2009","journal-title":"Lancet"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215002822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215002822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:35:40Z","timestamp":1652294140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215002822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0169500215002822"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.05.021","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}